Sellas Life Sciences (SLS) is a clinical-stage biopharma company with a significant valuation based on its late-stage drug, Gellen Pepums (GPS), for AML, making the upcoming trial data a critical binary event.
Source Post
Sellas Life Sciences Just Triggered a Massive 130% Rally Setup! | SLS Stock Analysis
Jul 6, 2026
This podcast episode analyzes Sellas Life Sciences (SLS), a clinical-stage biopharmaceutical company with no current commercial revenue but a valuation of a billion dollars. The stock has surged significantly due to its late-stage drug, Gellen Pepums (GPS), for acute myeloid leukemia (AML). The discussion focuses on the binary nature of the upcoming Phase 3 Regal trial data readout, which is crucial for the company's valuation, and the unique mechanism of GPS as a maintenance therapy.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.